Richard A. Gonzalez net worth and biography

Richard Gonzalez Biography and Net Worth

CEO of AbbVie
Richard A. Gonzalez is Chairman of the Board and Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 48,000 people worldwide and markets medicines in more than 175 countries. 

Prior to AbbVie’s separation from Abbott in January 2013, Mr. Gonzalez was a 30-year Abbott veteran. He served as President and Chief Operating Officer of Abbott before briefly retiring in 2007. He also held various senior leadership positions in Abbott’s medical products businesses, including President and Chief Operating Officer of the Medical Products Group; Senior Vice President and President of the former Hospital Products Division; Vice President and President of the Health Systems Division; and Divisional Vice President and General Manager for Diagnostics Operations in the United States and Canada. 

Mr. Gonzalez has been a long-standing leader in the greater Chicago community where he is a member of the Commercial Club of Chicago and represents AbbVie on their Civic Committee. He is also a member of the Business Roundtable, which is the only national organization representing exclusively CEOs of America’s leading companies.

What is Richard A. Gonzalez's net worth?

The estimated net worth of Richard A. Gonzalez is at least $73.81 million as of March 1st, 2021. Mr. Gonzalez owns 450,981 shares of AbbVie stock worth more than $73,807,550 as of December 3rd. This net worth evaluation does not reflect any other investments that Mr. Gonzalez may own. Additionally, Mr. Gonzalez receives a salary of $7,420,000.00 as CEO at AbbVie. Learn More about Richard A. Gonzalez's net worth.

How old is Richard A. Gonzalez?

Mr. Gonzalez is currently 68 years old. There are 7 older executives and no younger executives at AbbVie. Learn More on Richard A. Gonzalez's age.

What is Richard A. Gonzalez's salary?

As the CEO of AbbVie Inc., Mr. Gonzalez earned a total compensation package of $23,912,154.00 in 2021. Mr. Gonzalez earned a salary of $1,700,000.00, stock awards of $12,573,689.00, options awards of $3,134,649.00, non-equity compensation of $4,908,750.00, and other compensation of $814,073.00. Learn More on Richard A. Gonzalez's salary.

How do I contact Richard A. Gonzalez?

The corporate mailing address for Mr. Gonzalez and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Richard A. Gonzalez's contact information.

Has Richard A. Gonzalez been buying or selling shares of AbbVie?

Richard A. Gonzalez has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Richard A. Gonzalez sold 174,100 shares of the business's stock in a transaction on Thursday, December 9th. The shares were sold at an average price of $123.23, for a transaction totalling $21,454,343.00. Learn More on Richard A. Gonzalez's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 16 times. They sold a total of 997,100 shares worth more than $140,525,236.75. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Richard A. Gonzalez Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2021Sell174,100$123.23$21,454,343.00View SEC Filing Icon  
3/1/2021Sell170,113$108.61$18,475,972.93450,981View SEC Filing Icon  
12/11/2018Sell16,850$88.75$1,495,437.50286,203View SEC Filing Icon  
2/28/2018Sell8,280$117.88$976,046.40321,292View SEC Filing Icon  
11/21/2017Sell218,193$94.01$20,512,323.93492,030View SEC Filing Icon  
8/7/2017Sell193,131$71.00$13,712,301.00469,623View SEC Filing Icon  
8/4/2017Sell87,899$71.02$6,242,586.98342,353View SEC Filing Icon  
8/3/2017Sell65,861$71.00$4,676,131.00342,353View SEC Filing Icon  
5/19/2017Sell71,235$65.49$4,665,180.15349,462View SEC Filing Icon  
3/8/2017Sell72,016$64.25$4,627,028.00369,113View SEC Filing Icon  
6/2/2016Sell285,953$63.82$18,249,520.46624,374View SEC Filing Icon  
5/11/2016Sell39,000$63.80$2,488,200.00338,421View SEC Filing Icon  
4/28/2015Sell102,964$64.67$6,658,681.88View SEC Filing Icon  
See Full Table

Richard A. Gonzalez Buying and Selling Activity at AbbVie

This chart shows Richard A Gonzalez's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $163.66
Low: $160.51
High: $163.76

50 Day Range

MA: $148.46
Low: $134.21
High: $163.66

2 Week Range

Now: $163.66
Low: $117.00
High: $175.91


4,252,299 shs

Average Volume

6,597,847 shs

Market Capitalization

$289.43 billion

P/E Ratio


Dividend Yield